Analysis of promoter CpG island hypermethylation in cancer

Location, location, location!

Iris J H Van Vlodrop, Hanneke E C Niessen, Sarah Derks, Marcella M L L Baldewijns, Wim Van Criekinge, James G. Herman, Manon Van Engeland

Research output: Contribution to journalArticle

Abstract

The genetic and epigenetic alterations that underlie cancer pathogenesis are rapidly being identified. This provides novel insights in tumor biology as well as in potential cancer biomarkers. The somatic mutations in cancer genes that have been implemented in clinical practice are well defined and very specific. For epigenetic alterations, and more specifically aberrant methylation of promoter CpG islands, evidence is emerging that these markers could be used for the early detection of cancer as well as prediction of prognosis and response to therapy. However, the exact location of biologically and clinically relevant hypermethylation has not been identified for the majority of methylation markers. The most widely used approaches to analyze DNA methylation are based on primer- and probe-based assays that provide information for a limited number of CpG dinucleotides and thus for only part of the information available in a given CpG island. Validation of the current data and implementation of hypermethylation markers in clinical practice require a more comprehensive and critical evaluation of DNA methylation and limitations of the techniques currently used in methylation marker research. Here, we discuss the emerging evidence on the importance of the location of CpG dinucleotide hypermethylation in relation to gene expression and associations with clinicopathologic characteristics in cancer.

Original languageEnglish (US)
Pages (from-to)4225-4231
Number of pages7
JournalClinical Cancer Research
Volume17
Issue number13
DOIs
StatePublished - Jul 1 2011

Fingerprint

CpG Islands
Methylation
DNA Methylation
Epigenomics
Neoplasms
Neoplasm Genes
Tumor Biomarkers
Early Detection of Cancer
Biomarkers
Gene Expression
Mutation
Research
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Van Vlodrop, I. J. H., Niessen, H. E. C., Derks, S., Baldewijns, M. M. L. L., Van Criekinge, W., Herman, J. G., & Van Engeland, M. (2011). Analysis of promoter CpG island hypermethylation in cancer: Location, location, location! Clinical Cancer Research, 17(13), 4225-4231. https://doi.org/10.1158/1078-0432.CCR-10-3394

Analysis of promoter CpG island hypermethylation in cancer : Location, location, location! / Van Vlodrop, Iris J H; Niessen, Hanneke E C; Derks, Sarah; Baldewijns, Marcella M L L; Van Criekinge, Wim; Herman, James G.; Van Engeland, Manon.

In: Clinical Cancer Research, Vol. 17, No. 13, 01.07.2011, p. 4225-4231.

Research output: Contribution to journalArticle

Van Vlodrop, IJH, Niessen, HEC, Derks, S, Baldewijns, MMLL, Van Criekinge, W, Herman, JG & Van Engeland, M 2011, 'Analysis of promoter CpG island hypermethylation in cancer: Location, location, location!', Clinical Cancer Research, vol. 17, no. 13, pp. 4225-4231. https://doi.org/10.1158/1078-0432.CCR-10-3394
Van Vlodrop IJH, Niessen HEC, Derks S, Baldewijns MMLL, Van Criekinge W, Herman JG et al. Analysis of promoter CpG island hypermethylation in cancer: Location, location, location! Clinical Cancer Research. 2011 Jul 1;17(13):4225-4231. https://doi.org/10.1158/1078-0432.CCR-10-3394
Van Vlodrop, Iris J H ; Niessen, Hanneke E C ; Derks, Sarah ; Baldewijns, Marcella M L L ; Van Criekinge, Wim ; Herman, James G. ; Van Engeland, Manon. / Analysis of promoter CpG island hypermethylation in cancer : Location, location, location!. In: Clinical Cancer Research. 2011 ; Vol. 17, No. 13. pp. 4225-4231.
@article{6a6495998cca49c5ae046c00251bb1d2,
title = "Analysis of promoter CpG island hypermethylation in cancer: Location, location, location!",
abstract = "The genetic and epigenetic alterations that underlie cancer pathogenesis are rapidly being identified. This provides novel insights in tumor biology as well as in potential cancer biomarkers. The somatic mutations in cancer genes that have been implemented in clinical practice are well defined and very specific. For epigenetic alterations, and more specifically aberrant methylation of promoter CpG islands, evidence is emerging that these markers could be used for the early detection of cancer as well as prediction of prognosis and response to therapy. However, the exact location of biologically and clinically relevant hypermethylation has not been identified for the majority of methylation markers. The most widely used approaches to analyze DNA methylation are based on primer- and probe-based assays that provide information for a limited number of CpG dinucleotides and thus for only part of the information available in a given CpG island. Validation of the current data and implementation of hypermethylation markers in clinical practice require a more comprehensive and critical evaluation of DNA methylation and limitations of the techniques currently used in methylation marker research. Here, we discuss the emerging evidence on the importance of the location of CpG dinucleotide hypermethylation in relation to gene expression and associations with clinicopathologic characteristics in cancer.",
author = "{Van Vlodrop}, {Iris J H} and Niessen, {Hanneke E C} and Sarah Derks and Baldewijns, {Marcella M L L} and {Van Criekinge}, Wim and Herman, {James G.} and {Van Engeland}, Manon",
year = "2011",
month = "7",
day = "1",
doi = "10.1158/1078-0432.CCR-10-3394",
language = "English (US)",
volume = "17",
pages = "4225--4231",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "13",

}

TY - JOUR

T1 - Analysis of promoter CpG island hypermethylation in cancer

T2 - Location, location, location!

AU - Van Vlodrop, Iris J H

AU - Niessen, Hanneke E C

AU - Derks, Sarah

AU - Baldewijns, Marcella M L L

AU - Van Criekinge, Wim

AU - Herman, James G.

AU - Van Engeland, Manon

PY - 2011/7/1

Y1 - 2011/7/1

N2 - The genetic and epigenetic alterations that underlie cancer pathogenesis are rapidly being identified. This provides novel insights in tumor biology as well as in potential cancer biomarkers. The somatic mutations in cancer genes that have been implemented in clinical practice are well defined and very specific. For epigenetic alterations, and more specifically aberrant methylation of promoter CpG islands, evidence is emerging that these markers could be used for the early detection of cancer as well as prediction of prognosis and response to therapy. However, the exact location of biologically and clinically relevant hypermethylation has not been identified for the majority of methylation markers. The most widely used approaches to analyze DNA methylation are based on primer- and probe-based assays that provide information for a limited number of CpG dinucleotides and thus for only part of the information available in a given CpG island. Validation of the current data and implementation of hypermethylation markers in clinical practice require a more comprehensive and critical evaluation of DNA methylation and limitations of the techniques currently used in methylation marker research. Here, we discuss the emerging evidence on the importance of the location of CpG dinucleotide hypermethylation in relation to gene expression and associations with clinicopathologic characteristics in cancer.

AB - The genetic and epigenetic alterations that underlie cancer pathogenesis are rapidly being identified. This provides novel insights in tumor biology as well as in potential cancer biomarkers. The somatic mutations in cancer genes that have been implemented in clinical practice are well defined and very specific. For epigenetic alterations, and more specifically aberrant methylation of promoter CpG islands, evidence is emerging that these markers could be used for the early detection of cancer as well as prediction of prognosis and response to therapy. However, the exact location of biologically and clinically relevant hypermethylation has not been identified for the majority of methylation markers. The most widely used approaches to analyze DNA methylation are based on primer- and probe-based assays that provide information for a limited number of CpG dinucleotides and thus for only part of the information available in a given CpG island. Validation of the current data and implementation of hypermethylation markers in clinical practice require a more comprehensive and critical evaluation of DNA methylation and limitations of the techniques currently used in methylation marker research. Here, we discuss the emerging evidence on the importance of the location of CpG dinucleotide hypermethylation in relation to gene expression and associations with clinicopathologic characteristics in cancer.

UR - http://www.scopus.com/inward/record.url?scp=79960325679&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960325679&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-10-3394

DO - 10.1158/1078-0432.CCR-10-3394

M3 - Article

VL - 17

SP - 4225

EP - 4231

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 13

ER -